

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 8-K

Current Report
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 29, 2020

LeMaitre Vascular, Inc.
(Exact name of registrant as specified in its charter)

Commission File Number: 001-33092

Delaware
(State or other jurisdiction of
incorporation)

04-2825458
(IRS Employer
Identification No.)

63 Second Avenue
Burlington, MA 01803
(Address of principal executive offices, including zip code)

781-221-2266
(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by checkmark whether the company is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12c-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Securities registered pursuant to Section 12(b) of the Exchange Act:

Title of each class	Trading symbol	Name of exchange on which registered
Common stock, \$0.01 par value per share	LMAT	The Nasdaq Global Market

Item 2.02. Results of Operations and Financial Condition.

On October 29, 2020, LeMaitre Vascular, Inc. (the “Company”) issued a press release regarding its preliminary financial and operational results for the quarter ended September 30, 2020. A copy of the press release is furnished as Exhibit 99.1 to this Report.

The information in this Item 2.02, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

The following exhibits are furnished or filed as part of this Report, as applicable:

(d) Exhibits.

Exhibit No.	Description
99.1	Press release issued by LeMaitre Vascular, Inc. on October 29, 2020.
104	Cover Page Interactive Data File (embedded within the Inline XBRL document).

Exhibit Index

Exhibit No.	Description
99.1	Press release issued by LeMaitre Vascular, Inc. on October 29, 2020.

Signature(s)

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

LeMaitre Vascular, Inc.

Date: October 29, 2020

By: Joseph P. Pellegrino, Jr.
/s/ JOSEPH P. PELLEGRINO, JR.
Joseph P. Pellegrino, Jr.
Chief Financial Officer

LeMaitre Vascular Announces Q3 2020 Financial Results

BURLINGTON, MA, October 29, 2020 - LeMaitre Vascular, Inc. (Nasdaq:LMAT), a provider of vascular devices, implants and services, today reported Q3 2020 results and announced a \$0.095/share quarterly dividend.

Q3 2020 Results

- Sales of \$36.4mm, +25% (-3% organic) vs. Q3 2019
- Op. income of \$10.0mm, +70%
- Op. margin of 28%
- Net income of \$7.5mm, +45%
- Earnings of \$0.37 per diluted share, +44%
- EBITDA of \$12.6mm, +79%
- Cash & equivalents up \$9.3mm to \$34.4mm
- Debt down \$4.5mm to \$60.5mm

The Company posted sales growth in the Americas (+37%), Asia/Pac (+12%) and Europe/Middle East/Africa (+6%). The three recent acquisitions (Artegraft, CardioCel and Eze-Sit) and the return of elective surgery drove growth.

Gross margin decreased to 62.3% in Q3 2020 (vs. 69.3% in Q3 2019) primarily due to Artegraft purchase-price accounting.

Operating expenses decreased 11% to \$12.7mm in Q3 2020 (vs. \$14.3mm). This decline was driven by COVID-related cost-cuts, including reduced sales & marketing expenses.

Chairman & CEO George LeMaitre said, "Record sales in Q3 and tight expense control led to healthy bottom-line results and an improved balance sheet."

Business Outlook

	Guidance
Q4 2020 Sales	\$34.0mm - \$38.0mm (Midpoint: +19%)
Q4 2020 Gross Margin	65.5%
Q4 2020 Operating Income	\$7.1mm - \$9.7mm (Midpoint: +70%)
Q4 2020 Earnings Per Share	\$0.25 - \$0.35 (Midpoint: +32%)
2020 Sales	\$125.8mm - \$129.8mm (Midpoint: +9%)
2020 Gross Margin	65.6%
2020 Operating Income	\$26.3mm - \$28.9mm (Midpoint: +30%)
2020 Earnings Per Share	\$0.94 - \$1.04 (Midpoint: +12%)

Quarterly Dividend

On October 20, 2020, the Company's Board of Directors approved a quarterly dividend of \$0.095/share of common stock. The dividend will be paid on December 3, 2020 to shareholders of record on November 19, 2020.

Share Repurchase Program

On February 13, 2020, the Company's Board of Directors authorized the repurchase of up to \$10.0mm of the Company's common stock. The repurchase program may be suspended or discontinued at any time and will conclude on February 14, 2021, unless extended by the Board.

Conference Call Reminder

Management will conduct a conference call at 5:00 p.m. ET today to review the Company's Q3 2020 financial results. The conference call will be broadcast live over the Internet. Individuals interested in listening to the webcast can log on to the Company's website at www.lemaitre.com/investor. The conference call may also be accessed by dialing 844-239-5284 (+1 512-961-6497 for international callers), using passcode 4052529. For individuals unable to join the live conference call, a replay will be available on the Company's website.

A reconciliation of GAAP to non-GAAP results is included in the tables attached to this release.

About LeMaitre Vascular

LeMaitre Vascular is a provider of devices, implants and services for the treatment of peripheral vascular disease, a condition that affects more than 200 million people worldwide. The Company develops, manufactures and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon.

LeMaitre and the LeMaitre Vascular logo are registered trademarks of LeMaitre Vascular, Inc. This press release may include other trademarks and trade names of the Company.

For more information about the Company, please visit <http://www.lemaitre.com>.

Use of Non-GAAP Financial Measures

LeMaitre Vascular management believes that in order to better understand the Company's short-term and long-term financial trends, investors may wish to consider certain non-GAAP financial measures as a supplement to financial performance measures prepared in accordance with GAAP. Non-GAAP financial measures are not based on a comprehensive set of accounting rules or principles and do not have standardized meanings. These non-GAAP measures result from facts and circumstances that may vary in frequency and/or impact on continuing operations. Non-GAAP measures should be considered in addition to, and not as a substitute for, financial performance measures in accordance with GAAP. In addition to the description provided below, reconciliation of GAAP to non-GAAP results is provided in the financial statement tables included in this press release.

In this press release, the Company has reported non-GAAP sales growth percentages after adjusting for the impact of foreign currency exchange, business development transactions, and/or other events as well as EBITDA or earnings before interest, taxes, depreciation and amortization. The Company refers to the calculation of non-GAAP sales growth percentages as "organic." The Company analyzes non-GAAP sales on a constant currency basis, net of acquisitions and other non-recurring events, and EBITDA to better measure the comparability of results between periods. Because changes in foreign currency exchange rates have a non-operating impact on net sales, and acquisitions, divestitures, product discontinuations, and other strategic transactions are episodic in nature and are highly variable to the reported sales results, the Company believes that evaluating growth in sales on a constant currency basis net of such transactions provides an additional and meaningful assessment of sales to management. The Company believes that evaluating EBITDA provides an approximation of the cash generating ability of its operations.

The Company has also reported non-GAAP outstanding debt, which excludes the impact of unamortized deferred financing costs. The Company believes that considering its debt in this manner provides a view of the amount owed on a cash basis.

Forward-Looking Statements

The Company's current financial results, as discussed in this release, are preliminary and unaudited, and subject to adjustment. This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this press release regarding the Company's business that are not historical facts may be "forward-looking statements" that involve risks and uncertainties. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks and uncertainties that could cause actual results to differ from the results expected, including, but not limited to, the duration and severity of the impact of COVID-19 on the global economy, our customers, our suppliers and our company; the duration of the lapse in CE mark approval for certain of our devices; compliance with foreign regulatory requirements to market and sell our products outside the United States; the risk of significant fluctuations in our quarterly and annual results due to numerous factors; the risk that assumptions about the market for the Company's products and the productivity of the Company's direct sales force and distributors may not be correct; the risk that we may not be able to maintain our recent levels of profitability; the risk that the Company may not realize the anticipated benefits of its strategic activities; risks related to the integration of acquisition targets; the acceleration or deceleration of product growth rates; risks related to product demand and market acceptance of the Company's products and pricing; the risk that a recall of our products could result in significant costs or negative publicity; the risk that the Company is not successful in transitioning to a direct-selling model in new territories and other risks and uncertainties included under the heading "Risk Factors" in our most recent Annual Report on Form 10-K, as updated by our subsequent filings with the SEC, which are all available on the Company's investor relations website at <http://www.lemaitre.com> and on the SEC's website at <http://www.sec.gov>. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. The Company undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.

CONTACT: J.J. Pellegrino, CFO, LeMaitre Vascular
781-425-1691
jjpellegrino@lemaitre.com

LEMAITRE VASCULAR, INC (NASDAQ: LMAT)
CONDENSED CONSOLIDATED BALANCE SHEETS
(amounts in thousands)

	<u>September 30, 2020</u>	<u>December 31, 2019</u>
	(unaudited)	
Assets		
Current assets:		
Cash and cash equivalents	\$ 29,279	\$ 11,786
Short-term marketable securities	5,097	20,895
Accounts receivable, net	19,625	16,572
Inventory and other deferred costs	45,639	39,527
Prepaid expenses and other current assets	2,612	3,312
Total current assets	<u>102,252</u>	<u>92,092</u>
Property and equipment, net	14,133	14,854
Right-of-use leased assets	16,373	15,208
Goodwill	65,945	39,951
Other intangibles, net	60,539	24,893
Deferred tax assets	1,385	1,084
Other assets	942	259
Total assets	<u>\$ 261,569</u>	<u>\$ 188,341</u>
Liabilities and stockholders' equity		
Current liabilities:		
Current portion of long-term debt	\$ 2,250	\$ -
Revolving line of credit	21,000	-
Accounts payable	2,168	2,604
Accrued expenses	14,679	14,014
Acquisition-related obligations	2,543	2,476
Lease liabilities - short-term	1,806	1,757
Total current liabilities	<u>44,446</u>	<u>20,851</u>
Long-term debt	36,229	-
Lease liabilities - long-term	15,192	13,955
Deferred tax liabilities	90	1,179
Other long-term liabilities	4,629	4,215
Total liabilities	<u>100,586</u>	<u>40,200</u>
Stockholders' equity		
Common stock	218	217
Additional paid-in capital	109,640	105,934
Retained earnings	65,457	57,029
Accumulated other comprehensive loss	(3,009)	(4,007)
Treasury stock	(11,323)	(11,032)
Total stockholders' equity	<u>160,983</u>	<u>148,141</u>
Total liabilities and stockholders' equity	<u>\$ 261,569</u>	<u>\$ 188,341</u>

LEMAITRE VASCULAR, INC (NASDAQ: LMAT)
CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS

(amounts in thousands, except per share amounts)

(unaudited)

	For the three months ended		For the nine months ended	
	September 30, 2020	September 30, 2019	September 30, 2020	September 30, 2019
Net sales	\$ 36,416	\$ 29,100	\$ 91,818	\$ 87,062
Cost of sales	13,712	8,934	40,216	27,117
Gross profit	22,704	20,166	60,216	59,945
Operating expenses:				
Sales and marketing	5,157	7,429	17,788	22,887
General and administrative	5,901	4,551	16,425	14,026
Research and development	2,098	2,281	7,230	6,777
Gain on sale of building	(470)	-	(470)	-
Total operating expenses	12,686	14,261	41,873	43,690
Income from operations	10,018	5,905	19,243	16,255
Other income:				
Interest expense	(665)	-	(732)	-
Other income (loss), net	25	(15)	-	236
Income before income taxes	9,378	5,890	18,425	16,491
Provision for income taxes	1,865	706	-	3,170
Net income	\$ 7,513	5,184	\$ 14,187	13,321
Earnings per share of common stock				
Basic	\$ 0.37	0.26	\$ 0.70	0.68
Diluted	\$ 0.37	0.25	\$ 0.69	0.66
Weighted - average shares outstanding:				
Basic	20,254	19,871	20,201	19,731
Diluted	20,474	20,378	20,434	20,258
Cash dividends declared per common share	\$ 0.095	0.085	\$ 0.285	0.255

LEMAITRE VASCULAR, INC (NASDAQ: LMAT)
SELECTED NET SALES INFORMATION

(amounts in thousands)

(unaudited)

	For the three months ended				For the nine months ended			
	September 30, 2020		September 30, 2019		September 30, 2020		September 30, 2019	
	\$	%	\$	%	\$	%	\$	%
Net Sales by Geography								
Americas	\$ 24,184	66%	\$ 17,698	61%	\$ 57,462	63%	\$ 51,584	59%
Europe/Middle								
East/Africa	10,039	28%	9,452	32%	28,339	31%	29,479	34%
Asia/Pacific Rim	2,193	6%	1,950	7%	6,017	6%	5,999	7%
Total Net Sales	\$ 36,416	100%	\$ 29,100	100%	\$ 91,818	100%	\$ 87,062	100%

LEMAITRE VASCULAR, INC (NASDAQ: LMAT)

NON-GAAP FINANCIAL MEASURES

(amounts in thousands)

(unaudited)

Reconciliation between GAAP and Non-GAAP sales growth:

For the three months ended September 30, 2020			
Net sales as reported	\$	36,416	
Impact of currency exchange rate fluctuations		(484)	
Net impact of acquisitions excluding currency		(7,584)	
Adjusted net sales	\$	28,348	
For the three months ended September 30, 2019			
Net sales as reported	\$	29,100	
Adjusted net sales	\$	29,100	
Adjusted net sales increase for the three months ended September 30, 2020	\$	(752)	-3%

Reconciliation between GAAP and non-GAAP debt outstanding:

As of September 30, 2020			
Debt as reported	\$	59,479	
Add back unamortized deferred financing costs		1,021	
Adjusted debt outstanding	\$	60,500	

	For the three months ended		For the nine months ended	
	September 30, 2020	September 30, 2019	September 30, 2020	September 30, 2019
Reconciliation between GAAP and Non-GAAP EBITDA				
Net income as reported	\$ 7,513	\$ 5,184	\$ 14,187	\$ 13,321
Interest (income) expense, net	650	(193)	537	(574)
Amortization and depreciation expense	2,599	1,345	5,778	3,975
Provision for income taxes	1,865	706	4,238	3,170
EBITDA	\$ 12,627	\$ 7,042	\$ 24,740	\$ 19,892
EBITDA percentage increase		79%		24%